ALK(SZ:002940) Xin Lang Cai Jing·2025-09-04 06:34Company Overview - Zhejiang Angli Kang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018 [1] - The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] Revenue Composition - The revenue composition of the company is as follows: formulations account for 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Stock Performance - On September 4, the stock price of Angli Kang fell by 5.06%, closing at 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] Fund Holdings - According to data, one fund under Lobo Mai holds a significant position in Angli Kang, specifically the Lobo Mai China Healthcare Equity Fund A (020142), which held 35,500 shares, representing 4.5% of the fund's net value, making it the eighth largest holding [2] - The fund has a current size of 14.5216 million CNY and has achieved a year-to-date return of 46.7%, ranking 327 out of 4222 in its category [2] Fund Manager Performance - The fund manager of Lobo Mai China Healthcare Equity Fund A is Li Tao, who has been in the position for 1 year and 254 days, with total assets under management of 29.2458 million CNY [3] - During Li Tao's tenure, the best fund return was 17.87%, while the worst return was 16.66% [3]